These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 34586598)
21. How to fight SARS-COV-2 vaccine hesitancy in patients suffering from chronic and immune-mediated skin disease: four general rules. Campanati A; Martina E; Diotallevi F; Radi G; Kontochristopoulos G; Rigopoulos D; Gregoriou S; Offidani A Hum Vaccin Immunother; 2021 Nov; 17(11):4105-4107. PubMed ID: 34597526 [TBL] [Abstract][Full Text] [Related]
22. Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic. Yap C; Ali A; Prabhakar A; Prabhakar A; Pal A; Lim YY; Kakodkar P Ther Adv Vaccines Immunother; 2021; 9():25151355211059791. PubMed ID: 34870090 [TBL] [Abstract][Full Text] [Related]
23. Analysis of IgG, IgA and IgM antibodies against SARS-CoV-2 spike protein S1 in convalescent and vaccinated patients with the Pfizer-BioNTech and CanSinoBio vaccines. Melgoza-González EA; Hinojosa-Trujillo D; Reséndiz-Sandoval M; Mata-Haro V; Hernández-Valenzuela S; García-Vega M; Bravo-Parra M; Arvizu-Flores AA; Valenzuela O; Velázquez E; Soto-Gaxiola A; Gómez-Meza MB; Pérez-Jacobo F; Villela L; Hernández J Transbound Emerg Dis; 2022 Jul; 69(4):e734-e745. PubMed ID: 34655457 [TBL] [Abstract][Full Text] [Related]
24. Humoral and Cellular Immunogenicity of Six Different Vaccines against SARS-CoV-2 in Adults: A Comparative Study in Tunisia (North Africa). Ben Ahmed M; Bellali H; Gdoura M; Zamali I; Kallala O; Ben Hmid A; Hamdi W; Ayari H; Fares H; Mechri K; Marzouki S; Triki H; Ben Alaya N; Chahed MK; Klouz A; Sebai Ben Amor S; Ben Rayana C; Razgallah Khrouf M; Hamouda C; Elkadri N; Daghfous R; Trabelsi A Vaccines (Basel); 2022 Jul; 10(8):. PubMed ID: 35893838 [TBL] [Abstract][Full Text] [Related]
25. [Current state of vaccination against SARS-CoV-2]. Iking-Konert C; Specker C; Krüger K; Schulze-Koops H; Aries P Z Rheumatol; 2021 Mar; 80(2):158-164. PubMed ID: 33528655 [TBL] [Abstract][Full Text] [Related]
26. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021. Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735 [TBL] [Abstract][Full Text] [Related]
27. [BIOLOGICAL TREATMENT OF PSORIASIS IN TIME OF NEW CORONAVIRUS INFECTION COVID-19]. Kruglova LS; Pereverzina NO; Rudneva NS; Kamynina NN; Oynotkinova OS Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2021 Aug; 29(Special Issue):1381-1387. PubMed ID: 34792893 [TBL] [Abstract][Full Text] [Related]
28. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore. Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588 [TBL] [Abstract][Full Text] [Related]
29. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study. Haas EJ; McLaughlin JM; Khan F; Angulo FJ; Anis E; Lipsitch M; Singer SR; Mircus G; Brooks N; Smaja M; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S Lancet Infect Dis; 2022 Mar; 22(3):357-366. PubMed ID: 34562375 [TBL] [Abstract][Full Text] [Related]
30. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021. Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ; MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654 [TBL] [Abstract][Full Text] [Related]
31. Comparing the human milk antibody response after vaccination with four COVID-19 vaccines: A prospective, longitudinal cohort study in the Netherlands. Juncker HG; Mulleners SJ; Ruhé EJM; Coenen ERM; Bakker S; van Doesburg M; Harinck JE; Rood RD; Bouhuijs JH; Oomen M; de Groot PCJM; Pajkrt PD; Korosi A; van Goudoever PJB; van Gils MJ; van Keulen BJ EClinicalMedicine; 2022 May; 47():101393. PubMed ID: 35465077 [TBL] [Abstract][Full Text] [Related]
32. The Uro-oncology Patient and Vaccination Against SARS-CoV-2. Rodriguez Socarrás M; Gómez Rivas J; Teoh JY; Puente J; Moschini M; Moreno-Sierra J Eur Urol Open Sci; 2021 Jul; 29():77-81. PubMed ID: 34075362 [TBL] [Abstract][Full Text] [Related]
33. Impact of Obesity on Vaccination to SARS-CoV-2. Nasr MC; Geerling E; Pinto AK Front Endocrinol (Lausanne); 2022; 13():898810. PubMed ID: 35795152 [TBL] [Abstract][Full Text] [Related]
34. Developmental Status of the Potential Vaccines for the Mitigation of the COVID-19 Pandemic and a Focus on the Effectiveness of the Pfizer-BioNTech and Moderna mRNA Vaccines. Noor R Curr Clin Microbiol Rep; 2021; 8(3):178-185. PubMed ID: 33686365 [TBL] [Abstract][Full Text] [Related]
35. Finally, an FDA Approval for an Immunization Against COVID-19: Hope on the Horizon. Powell J; Piszczatoski CR Ann Pharmacother; 2022 Sep; 56(9):1058-1064. PubMed ID: 35012364 [TBL] [Abstract][Full Text] [Related]
36. Coronavirus disease 2019 vaccination in patients with psoriasis: A position statement from India by SIG psoriasis (IADVL Academy). Parthasaradhi A; Ganguly S; Kar BR; Thomas J; Neema S; Tahiliani S; Sathishkumar D; Parasramani SG; Chalam KV; Komeravalli H Indian J Dermatol Venereol Leprol; 2022; 88(3):286-290. PubMed ID: 35434988 [TBL] [Abstract][Full Text] [Related]
37. Review of COVID-19 Vaccines Approved in the United States of America for Emergency Use. Vasireddy D; Atluri P; Malayala SV; Vanaparthy R; Mohan G J Clin Med Res; 2021 Apr; 13(4):204-213. PubMed ID: 34007358 [TBL] [Abstract][Full Text] [Related]
38. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines. Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093 [TBL] [Abstract][Full Text] [Related]
39. [Position paper of the Italian Society of Cardiology (SIC) on COVID-19 vaccine priority in patients with cardiovascular diseases]. Indolfi C; Barillà F; Basso C; Ciccone MM; Curcio A; Mancone M; Mercuro G; Muscoli S; Nodari S; Pedrinelli R; Romeo F; Sinagra G; Filardi PP G Ital Cardiol (Rome); 2021 May; 22(5):363-375. PubMed ID: 33960979 [TBL] [Abstract][Full Text] [Related]
40. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Akova M; Unal S Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]